Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Alvotech (NASDAQ:ALVO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Insider & Institutional Ownership
25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for Senti Biosciences and Alvotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 2 | 1 | 2.75 |
| Alvotech | 2 | 2 | 4 | 0 | 2.25 |
Volatility and Risk
Senti Biosciences has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Profitability
This table compares Senti Biosciences and Alvotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -1,629.80% | -119.72% |
| Alvotech | -36.31% | -11.92% | -11.73% |
Earnings and Valuation
This table compares Senti Biosciences and Alvotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $55,000.00 | 188.34 | -$61.44 million | ($1.77) | -0.19 |
| Alvotech | $491.95 million | 3.26 | $27.92 million | ($0.61) | -8.72 |
Alvotech has higher revenue and earnings than Senti Biosciences. Alvotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Senti Biosciences beats Alvotech on 9 of the 15 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
